For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Licensing revenue | - | 0* | 0 | 0 |
| Research and development | 13,390,000 | 12,107,500* | 12,826,000 | 16,415,000 |
| General and administrative | 6,909,000 | 5,407,000* | 2,991,000 | 4,651,000 |
| Total operating expenses | 20,299,000 | 17,514,500* | 15,817,000 | 21,066,000 |
| Loss from operations | -20,299,000 | -17,514,500* | -15,817,000 | -21,066,000 |
| Interest income | 1,982,000 | 2,235,500* | 1,558,000 | 1,185,000 |
| Net loss | -18,317,000 | -15,279,000* | -14,259,000 | -19,881,000 |
| Unrealized loss on marketable securities | -439,000 | -56,000* | 66,000 | 18,000 |
| Comprehensive loss | -18,756,000 | -15,335,000 | -14,193,000 | -19,863,000 |
| Basic EPS | -0.1 | -0.092 | -0.08 | -0.14 |
| Basic Average Shares | 186,400,000 | 166,021,000 | 168,782,000 | 138,282,000 |
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX)